Read the newsletter by clicking here.
Swedish Summer is over and, at Xintela, we are preparing for an exciting Autumn. Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
The purpose of our newsletter is to provide a better understanding of Xintela's operations, to update readers on the company's development and to comment on the status of our projects. In this newsletter, we will provide an update on XACT (Xintela Assay for Cell Therapy), which is Xintela's quality test for cartilage cells and stem cells. In addition to giving a better insight into how XACT works, we will provide information on how we have further strengthened the project through the acquisition late last year of antibodies for another marker, integrin α11β1.
It is also noteworthy that a report from Global Data predicts that the sales of drugs for the treatment of glioblastoma will increase significantly in the next eight years. Treatments today are insufficient and there is great interest in identifying new methods and new target molecules for the treatment of glioblastoma. In our newsletter you can read an interview in BioStock where I responded to questions regarding our glioblastoma project.
CEO Xintela AB
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO